Karen H. Brock

Mutagenicity and clastogenicity of teniposide (VM-26) in L5178Y/TK +/- -3.7.2C mouse lymphoma cells.

The antitumor drug teniposide (VM-26) is a potent inducer of DNA breaks (Long et al., Cancer Res., (1985) 45, 3106), but it is only weakly mutagenic at the hprt locus in CHO cells (Singh and Gupta, Cancer Res., (1983) 43, 577). In the present study, the mutagenic and clastogenic activities of teniposide were evaluated in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. Although teniposide is a weak mutagen at the hprt locus, it is a potent mutagen at the tk locus, with as little as 0.5 ng/ml producing 220 TK mutants/10(6) survivors at 96% survival (background = 100/10(6) survivors). This same dose of teniposide induced 38 aberrations per 100 metaphases (background = 7/100 cells). At 7 ng/ml, teniposide induced approximately 2700 TK mutants/10(6) survivors at approximately 10% survival. At the highest dose sampled for aberration analysis (5 ng/ml), teniposide induced 44 aberrations/100 cells. Most of the aberrations were chromosomal rather than chromatid events. As expected for a compound acting primarily by a clastogenic mechanism, most of the TK mutants were small colonies. Thus, teniposide is a potent clastogen, and it is a potent mutagen at the tk locus but not at the hprt locus. These results support the hypothesis that the location of the target gene affects the ability of the assay to detect both intragenic events and events causing functional multilocus effects. Thus, a heterozygous locus (like tk) but not a functionally hemizygous locus (like hprt) may permit the detection of mutagens that act primarily by a clastogenic mechanism. Because teniposide induces topoisomerase II-associated DNA breaks, and because there is evidence that teniposide may not interact directly with DNA, we discuss the possibility that the potent clastogenic/mutagenic activity of teniposide may be mediated by topoisomerase II.

Mutagenicity and clastogenicity of proflavin in L5178Y/TK+/−−3.7.2.C cells

We evaluated the ability of proflavin to induce specific-locus mutations at the heterozygous thymidine kinase (tk) locus of L5178Y/TK +/- -3.7.2C mouse lymphoma cells, which appears to permit the recovery of mutants due to single-gene and chromosomal mutations. Proflavin was highly mutagenic at the tk locus, producing 724-965 TK mutants/10(6) survivors (background = 56-85/10(6); survival = 29-32%). Most of the mutants were small colonies, which suggested that proflavin may induce chromosomal mutations. The potent clastogenicity of proflavin was confirmed by cytogenetic analysis for chromosomal aberrations. At the highest dose analyzed (1.5 micrograms/ml), proflavin produced 82 aberrations/100 metaphaes (background = 2/100). The large-colony TK mutant frequency produced by proflavin (48-109/10(6) survivors; background = 23/10(6); survival = 57-61%) was similar to published HPRT mutant frequencies produces by proflavin in L5178Y and CHO cells (50-100/10(6) survivors; background = 2-50/10(6); survival = 50-62%). These results lead to the conclusion that proflavin is a potent clastogen and induces a high frequency of small-colony TK mutants; however, it induces a low frequency of HPRT mutants and a low frequency of large-colony TK mutants.

Mutagenicity and clastogenicity of adriamycin in L5178Y/TK+/−-3.7.2C mouse lymphoma cells

Adriamycin was found to be both mutagenic and clastogenic to L5178Y/TK(+/-)-3.7.2C mouse lymphoma cells. A dose of only 5 ng/ml (survival = 62% or 67%) gave an induced TK mutant frequency of 307 or 296 per 10(6) survivors in two separate experiments. This dose was also clastogenic, inducing 20 chromosome aberrations/100 cells analyzed. The majority of the mutants were small-colony mutants, indicating that adriamycin likely acts primarily by a clastogenic mechanism.

Mutagenicity of actinomycin D in mammalian cells due to clastogenic effects.

Actinomycin D was clastogenic and mutagenic in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. The majority of the mutants were small colonies, indicating that actinomycin D acts primarily by a clastogenic mechanism.

Induced hepatocytes as a metabolic activation system for the mouse-lymphoma assay

We have developed methods for the coculture of hepatocytes and mouse lymphoma cells and have shown that this system can be used for evaluating promutagens from several chemical classes (Brock et al., 1987). In the present study we investigated the use of hepatocytes isolated from rats pretreated with a cytochrome P-450 inducer (PB) or a P-448 inducer (BNF). CP-induced mutagenicity was higher in the presence of PB-induced hepatocytes than in control hepatocytes. Control and BNF-induced hepatocytes were evaluated with B(a)P, B(l)A, and BA. A dose-related positive response was observed with B(a)P and B(l)A both in the presence of control or induced hepatocytes; however, somewhat higher mutant frequencies were obtained in the presence of BNF-induced hepatocytes. BA induced a very weak positive response (approx. 2 X b.g.) in the presence of control hepatocytes and was weakly positive in the presence of BNF-induced hepatocytes. Benzene was tested using control and both PB- and BNF-induced hepatocytes. Neither of these approaches were successful in activating benzene to a mutagenic metabolite. These studies indicate that for some chemicals the mutagenic response of mouse lymphoma cells can be increased by inducing hepatocytes prior to isolation and cocultivation, and expands the use of hepatocytes for research evaluating chemicals requiring metabolic activation.

Genotoxicity studies of benz[l]aceanthrylene

The genotoxicity of the cyclopenta-fused polycyclic aromatic hydrocarbon, benz[l]aceanthrylene (B[l]A), was evaluated in vitro using the L5178Y/TK+/- mouse lymphoma assay and in vivo using the mouse peripheral blood lymphocyte (PBL) culture system. The mutagenicity and sister chromatid exchange (SCE) inducing potential of B[l]A was then compared to that of benzo[a]pyrene (B[a]P). B[l]A appeared to be slightly less mutagenic than B[a]P at the TK locus, and each compound produced both small and large colony mutants indicating that they are clastogenic as well as mutagenic. Gross chromosome aberration analysis of treated L5178Y/TK+/- mouse lymphoma cells confirmed the clastogenicity of B[l]A in vitro. In the mouse PBL system, after administration by gavage, B[l]A was more cytotoxic and produced a sharper elevation in SCE frequency than B[a]P.

Sister Chromatid Exchange Analysis in Lymphocytes

Sister chromatid exchanges (SCEs) are generally considered to arise from breakage and recombination of sister chromatid segments at homologous loci.(1) Although the fundamental nature of SCE is not well understood, interests in its frequency have been central both to historical and current studies. Early autoradiographic techniques used to detect this phenomenon were applied for a variety of investigations into its spontaneous and irradiationrelated incidences in somatic and germ cells.(2,3) Nearly a decade ago technically simpler bromodeoxyuridine (BrdUrd)-differential staining methodology was developed in a cultured human lymphocyte system and shown to provide much superior resolving power.(4) Chemical mutagens were clearly demonstrated to induce SCEs at significantly lower doses than those required to cause chromosome aberrations.(5,6) This observation coincided with timely autoradiographic determinations of mutagen action in SCE formation(7,8) and set a new course of emphasis — SCE induction stemming from exposure to environmental agents. The BrdUrd methodology has since been extended to a wide variety of in vitro and in vivo cellular systems, and hundreds of SCE induction trials have implicated numerous chemical, physical (i.e., UV irradiation), and biological (i.e., virus) agents in the production of this effect(9,10) A recent summary evaluation of accumulated results has concluded that most chemical carcinogens induce SCEs, the test being particularly sensitive to agents that cause DNA adducts.(1)